Patents by Inventor Tak Wah Mak

Tak Wah Mak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE
    Publication number: 20230390294
    Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
    Type: Application
    Filed: August 18, 2023
    Publication date: December 7, 2023
    Inventors: Mark Robert Bray, Jacqueline M. Mason, Tak Wah Mak, Graham Fletcher
  • COMBINATION THERAPIES FOR INHIBITION OF POLO-LIKE KINASE 4
    Publication number: 20210060026
    Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 4, 2021
    Inventors: Jacqueline M. Mason, Mark R. Bray, Tak Wah Mak, Graham Fletcher
  • Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
    Patent number: 10024844
    Abstract: Disclosed are methods for treating a subject with an EGFR dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that decreases the biological activity of iRhom1 and an effective amount of an agent (“Second Agent”) that decreases the biological activity of iRhom2. Alternatively, the method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (“Second Agent”) that modulates formation of a complex between TACE and iRhom2. Also disclosed are assays for identifying such agents.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 17, 2018
    Assignees: Hospital for Special Surgery, University Health Network
    Inventors: Carl Blobel, Thorsten Maretzky, David McIlwain, Tak Wah Mak
  • TREATMENT OF EGF-RECEPTOR DEPENDENT PATHOLOGIES
    Publication number: 20150316538
    Abstract: Disclosed are methods for treating a subject with an EGFR dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that decreases the biological activity of iRhom1 and an effective amount of an agent (“Second Agent”) that decreases the biological activity of iRhom2. Alternatively, the method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (“Second Agent”) that modulates formation of a complex between TACE and iRhom2. Also disclosed are assays for identifying such agents.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 5, 2015
    Inventors: Carl Blobel, Thorsten Maretzky, David McIlwain, Tak Wah Mak
  • Method for the treatment of multiple sclerosis
    Patent number: 9132138
    Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of 2ME2 or a derivative thereof.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: September 15, 2015
    Assignee: CASI Pharmaceuticals, Inc.
    Inventors: Tak Wah Mak, Gordon Stuart Duncan
  • IRHOM2 INHIBITION FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS
    Publication number: 20150241429
    Abstract: Disclosed are methods for treating a subject with a Complement mediated (e.g., C5a mediated) disease or an immune complex mediated disease. The method comprises the step of administering to the subject an effective amount of an agent that decreases the biological activity of iRhom2 or an agent that modulates formation of a complex between iRhom2 and TACE. Also disclosed are assays for identifying such agents.
    Type: Application
    Filed: September 11, 2013
    Publication date: August 27, 2015
    Inventors: Priya Issuree, Thorsten Maretzky, David McIlwain, Tak Wah Mak, Carl Blobel, Jane Salmon
  • Method for the Treatment of Multiple Sclerosis
    Publication number: 20140056848
    Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of 2ME2 or a derivative thereof.
    Type: Application
    Filed: March 8, 2013
    Publication date: February 27, 2014
    Applicant: ENTREMED, INC.
    Inventors: Tak Wah Mak, Gordon Stuart Duncan
  • Downregulation of immune response by administering B7RP-2 fusion protein
    Patent number: 7482325
    Abstract: The present invention provides B7 Related Protein-2 (B7RP-2) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7RP-2 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7RP-2 polypeptides.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: January 27, 2009
    Assignee: Amgen Inc.
    Inventors: Steven Kiyoshi Yoshinaga, Woong-Kyung Suh, Tak Wah Mak
  • CD45 disrupted nucleic acid
    Patent number: 6664107
    Abstract: A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: December 16, 2003
    Assignee: Ontario Cancer Institute, University Health Network
    Inventors: Tak Wah Mak, Kenji Kishihara
  • Transgenic mice comprising CD45 knockout
    Patent number: 6552246
    Abstract: A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: April 22, 2003
    Assignee: University Health Network
    Inventors: Tak Wah Mak, Josef Martin Penninger
  • B7 related protein-2 molecules and uses thereof
    Publication number: 20030039999
    Abstract: The present invention provides B7 Related Protein-2 (B7RP-2) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7RP-2 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7RP-2 polypeptides.
    Type: Application
    Filed: May 28, 2002
    Publication date: February 27, 2003
    Applicant: Amgen, Inc.
    Inventors: Steven Kiyoshi Yoshinaga, Woong-Kyung Suh, Tak Wah Mak
  • Methods of inhibiting syp binding to a CTLA-4 receptor
    Patent number: 5786152
    Abstract: Disclosed are methods for identifying a molecule that inhibits SYP activity in a T-cell.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: July 28, 1998
    Assignee: Amgen Inc.
    Inventors: Luc Edgar Joseph Marengere, David Peter Siderovski, Tak Wah Mak
  • Mice lacking expression of CTLA-4 receptor
    Patent number: 5714667
    Abstract: Disclosed is a mouse in which expression of the gene encoding the CTLA-4 receptor is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: February 3, 1998
    Assignee: Amgen Canada Inc.
    Inventors: Paul David Waterhouse, Tak Wah Mak